FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	ourden
hours per response.	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Welgus Howard G.						2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ ARQT ]								ionship of Reporting all applicable) Director		10% Owr		ner
(Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD, SUITE 300					02	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021								Officer (give title below)		Other (spec below)		
(Street) WESTL	(C)	A	91361		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							i. Indiv ine) X	<b>'</b>				
(City)	(S	tate)	(Zip)															
		Tab	le I - I	Non-Deri	vativ	e Sec	urities A	cquir	ed, C	)isposed	of, or E	Benefici	ally	Owned	t			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		Execution Date,				s Acquired (A) or If (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct of direct E	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)			(	(Instr. 4)	
Common	Stock			02/01/2	021			<b>M</b> <sup>(1)</sup>		380	Α	\$1.68	06	18:	3,498	D		
Common	Stock			02/01/2	021			<b>M</b> <sup>(1)</sup>		1,820	A	\$1.68	06	185,318		D		
Common	Stock			02/01/2	021			S <sup>(1)</sup>		550	D	\$33.45	45(2)	184,768		D		
Common	Stock			02/01/2	021			<b>S</b> <sup>(1)</sup>		1,250	D	\$34.49	)1 <sup>(3)</sup>	183,518		D		
Common	Stock			02/01/2	021			S <sup>(1)</sup>		350	D	\$35.02	43(4)	183,168		B D		
Common	Stock			02/01/2	021			S <sup>(1)</sup>		50	D	\$36	5	183,118		,118 D		
Common	Stock													24,991		I		By Frust <sup>(5)</sup>
		7	able							sposed of				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execu if any	3A. Deemed Execution Date,		action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exer Expiration I (Month/Day		cisable and	7. Title a Amount Securiti Underly	and t of ies ring ive Securit	8. De Se (In	erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly Di or	wnership orm: rect (D) Indirect (Instr. 4)	11. Nature of Indirec Beneficia Ownershi (Instr. 4)
												Amoun or Numbe						

## **Explanation of Responses:**

\$1.6806

\$1,6806

Stock Option

(Right to Buy)

Stock

Ontion

(Right to

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

02/01/2021

02/01/2021

2. The transaction was executed in multiple trades in prices ranging from \$33.00 to \$33.89, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Date

Exercisable

(6)

(6)

(D)

380

1,820

(A)

Code

**M**<sup>(1)</sup>

**M**<sup>(1)</sup>

Expiration

03/13/2029

03/13/2029

Title

Stock

Commor

Stock

Shares

380

1.820

\$0.00

\$0.00

12,896

27 333

D

D

Date

- 3. The transaction was executed in multiple trades in prices ranging from \$34.00 to \$34.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 4. The transaction was executed in multiple trades in prices ranging from \$35.00 to \$35.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 5. The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes
- 6. The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase

/s/ John W. Smither, as 02/03/2021 Attorney-in-Fact for Howard

G. Welgus

\*\* Signature of Reporting Person

Date

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.